AlloVir (NASDAQ:ALVR) Stock, Quote.Headers.trade-ideas

AlloVir

AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.

Long Ideas

News

Penny Stocks

Pre-Market Outlook

Markets

Trading Ideas

ALVR

ALPS ETF Trusthen & Steers Global Realty Majors ETF

IBIO

VYNE

The most oversold stocks in the health care presents an opportunity to buy into undervalued companies.

Top 4 Health Care Stocks That May Rocket Higher In Q1

Price Target

Small Cap

Analyst Ratings

CTSH

HBAN

KRTX

PAYX

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Cognizant Technology Solutions To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Tuesday

Earnings

Eurozone

Commodities

Global

Intraday Update

DSKE

NCPL

RMCO

U.S. stocks traded mixed toward the end of trading, with the Dow Jones index turning lower on Friday.

The Dow traded down 0.05% to 37,385.32 while the NASDAQ rose 0.12% to 14,982.36. The S&amp;P 500 also rose, gaining, 0.15% to 4,753.64.

Dow Edges Lower; Nike Sales Miss Estimates

AlloVir Inc

Alvarion Ltd

The most oversold stocks in the health care presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#39;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#39;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi"> RSI is below 30</a>, according to <a href="https://pro.benzinga.com/"> Benzinga Pro</a>.
Here&rsquo;s the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3>iBio, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ibio#NYSE">IBIO</a>)</h3>
<ul>
<li>On Dec. 5, iBio announced pricing of a $4.5 million public offering. The company&rsquo;s stock fell around 11% over the past five days and has a <a href="https://www.benzinga.com/quote/IBIO">52-week low of $1.16 </a>.</li>
<li>RSI Value: 23.25</li>
<li>IBIO Price Action: Shares of iBio fell 4.9% to close at $1.17 on Friday.</li>
</ul>
<h3>GRI Bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gri#NASDAQ">GRI</a>)</h3>
<ul>
<li>On Dec. 5, the company announced the initiation of patient enrollment in the Phase 2a biomarker study evaluating GRI-0621 for the treatment of IPF. The company&rsquo;s stock fell around 23% over the past month. It <a href="https://www.benzinga.com/quote/GRI"> has a 52-week low </a> of $0.2838.</li>
<li>RSI Value: 27.58</li>
<li>GRI Price Action: Shares of GRI Bio fell 3% to close at $0.3152 on Friday.</li>
</ul>
<h3>AlloVir, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alvr#NASDAQ">ALVR</a>)</h3>
<ul>
<li>On Jan. 1, 2024, AlloVir board approved a reduction its workforce by approximately 95% of current employee base to reduce costs and preserve capital. The company&rsquo;s stock fell around 69% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/ALVR"> low of $0.6230.</a></li>
<li>RSI Value: 28.16</li>
<li>ALVR Price Action: Shares of AlloVir gained 5.3% to close at $0.6950 on Friday.</li>
</ul>
<h3>VYNE Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vyne#NASDAQ">VYNE</a>)</h3>
<ul>
<li>On Nov. 13, VYNE Therapeutics posted a narrower-than-expected quarterly loss. &ldquo;We have made substantial progress in advancing our business in recent months,&rdquo; said David Domzalski, President and Chief Executive Officer of VYNE. &ldquo;With positive results from our Phase 1b trial, we believe there is strong support to advance VYN201 as a potential category-leading therapy in the treatment of vitiligo.&rdquo; The company&rsquo;s shares lost around 24% over the past month. The company&rsquo;s 52-week low is $2.00.</li>
<li>RSI Value: 28.98</li>
<li>VYNE Price Action: Shares of VYNE Therapeutics fell 2.8% to close at $2.06 on Friday.</li>
</ul>
&nbsp;
Read More: <a href="https://www.benzinga.com/news/24/01/36609836/beat-inflation-with-these-3-high-yielding-dividend-stocks-in-health-care-sector-from-wall-streets-mo"> Beat Inflation With These 3 High-Yielding Dividend Stocks In Health Care Sector From Wall Street&#39;s Most Accurate Analysts </a>

The move follows&nbsp;AlloVir&rsquo;s announcement on December&nbsp;22, 2023 that it is discontinuing its&nbsp;three global Phase 3 posoleucel studies. This workforce reduction will take place primarily during the first quarter of 2024 and expects to be substantially completed by April&nbsp;15, 2024. As a result of these actions, AlloVir expects to incur personnel-related restructuring charges of approximately $13&nbsp;million in connection with&nbsp;one-time&nbsp;employee termination cash expenditures, including severance and other benefits, which are expected to be substantially incurred in the first quarter of 2024.

On January 1, 2024, AlloVir Board Approved Reduction Its Workforce By Approximately 95% Of Current Employee Base To Reduce Costs And Preserve Capital - Filing

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>HC Wainwright &amp; Co. raised Karuna Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/krtx#NASDAQ">KRTX</a>) price target from $300 to $330. HC Wainwright &amp; Co. analyst Raghuram Selvaraju downgraded the stock from Buy to Neutral. Karuna Therapeutics shares jumped 47.7% to close at $317.85 on Friday. <a href="https://www.benzinga.com/quote/KRTX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities cut the price target for AlloVir, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alvr#NASDAQ">ALVR</a>) from $17 to $1. B of A Securities analyst Jason Zemansky downgraded the stock from Buy to Underperform. AlloVir shares fell 67.2% to close at $0.7654 on Friday. <a href="https://www.benzinga.com/quote/ALVR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Raymond James boosted the price target for Farmland Partners Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fpi#NYSE">FPI</a>) from $14 to $15. Raymond James analyst Buck Horne maintained an Outperform rating. Farmland Partners shares gained 1.3% to close at $12.76 on Friday. <a href="https://www.benzinga.com/quote/FPI/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Citigroup cut the price target for Paychex, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/payx#NASDAQ">PAYX</a>) from $130 to $125. Citigroup analyst Peter Christiansen maintained a Neutral rating. Paychex shares rose 0.8% to close at $119.86 on Friday. <a href="https://www.benzinga.com/quote/PAYX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. slashed the price target for Equillium, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eq#NASDAQ">EQ</a>) from $4.5 to $4. HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintained a Buy rating. Equillium shares fell 0.3% to close at $0.6570 on Friday. S<a href="https://www.benzinga.com/quote/EQ/analyst-ratings">ee how other analysts view this stock.</a></li>
<li>Truist Securities cut Omega Healthcare Investors, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ohi#NYSE">OHI</a>) price target from $34 to $31. Truist Securities analyst Michael Lewis maintained a Hold rating. Omega Healthcare Investors shares fell 0.1% to close at $30.70 on Friday. <a href="https://www.benzinga.com/quote/OHI/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Raymond James raised Huntington Bancshares Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hban#NASDAQ">HBAN</a>) price target from $13 to $15. Raymond James analyst David Long maintained a Strong Buy rating. Huntington Bancshares shares gained 0.2% to close at $12.66 on Friday. <a href="https://www.benzinga.com/quote/HBAN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wedbush boosted Cognizant Technology Solutions Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ctsh#NASDAQ">CTSH</a>) price target from $75 to $85. Wedbush analyst Moshe Katri maintained an Outperform rating. Cognizant Technology shares gained 1.3% to close at $75.15 on Thursday. <a href="https://www.benzinga.com/quote/CTSH/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>DA Davidson increased Modine Manufacturing Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mod#NYSE">MOD</a>) price target from $60 to $80. DA Davidson analyst Matt Summerville maintained a Buy rating. Modine Manufacturing shares gained 1.5% to close at $58.67 on Friday. <a href="https://www.benzinga.com/quote/MOD/analyst-ratings">See how other analysts view this stock.</a></li>
<li>BMO Capital increased CMS Energy Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cms#NYSE">CMS</a>) price target from $61 to $64. BMO Capital analyst James Thalacker maintained an Outperform rating. CMS Energy shares gained 0.6% to close at $57.23 on Friday. S<a href="https://www.benzinga.com/quote/CMS/analyst-ratings">ee how other analysts view this stock.</a></li>
</ul>
&nbsp;
Check This Out: <a href="https://www.benzinga.com/news/23/12/36358246/nike-posts-downbeat-sales-joins-netease-and-other-big-stocks-moving-lower-in-fridays-pre-market-sess"> Nike Posts Downbeat Sales, Joins NetEase And Other Big Stocks Moving Lower In Friday&#39;s Pre-Market Session </a>

B of A Securities analyst Jason Zemansky downgrades AlloVir (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVR#NASDAQ">ALVR</a>) from Buy to Underperform and lowers the price target from $17 to $1.

Downgrades

B of A Securities Downgrades AlloVir to Underperform, Lowers Price Target to $1

<h3>Gainers</h3>
<ul>
<li>Jin Medical International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZJYL#NASDAQ">ZJYL</a>) shares moved upwards by 94.4% to $137.0 during Monday's regular session. The market value of their outstanding shares is at $1.0 billion. </li>
<li>Karuna Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRTX#NASDAQ">KRTX</a>) stock increased by 47.71% to $317.87. The market value of their outstanding shares is at $11.9 billion. </li>
<li>IMAC Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BACK#NASDAQ">BACK</a>) shares moved upwards by 42.59% to $2.31. The market value of their outstanding shares is at $2.6 million. </li>
<li>Pasithea Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTTA#NASDAQ">KTTA</a>) shares rose 32.86% to $0.38. The market value of their outstanding shares is at $7.9 million. </li>
<li>PureTech Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTC#NASDAQ">PRTC</a>) stock moved upwards by 31.3% to $25.0. The market value of their outstanding shares is at $679.8 million. </li>
<li>Renalytix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNLX#NASDAQ">RNLX</a>) shares increased by 30.4% to $0.45. The company's market cap stands at $22.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>AlloVir (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVR#NASDAQ">ALVR</a>) stock fell 66.2% to $0.79 during Monday's regular session. The company's market cap stands at $89.7 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares decreased by 23.89% to $2.74. The market value of their outstanding shares is at $2.3 million. </li>
<li>60 Degrees (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTP#NASDAQ">SXTP</a>) shares decreased by 17.28% to $0.91. The market value of their outstanding shares is at $5.2 million. </li>
<li>HOOKIPA Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOK#NASDAQ">HOOK</a>) shares fell 16.41% to $0.72. The market value of their outstanding shares is at $60.5 million. </li>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) shares fell 15.24% to $0.43. The company's market cap stands at $7.3 million. </li>
<li>Nanobiotix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBTX#NASDAQ">NBTX</a>) stock declined by 14.72% to $6.55. The market value of their outstanding shares is at $308.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BACK

CYCC

HOOK

KTTA

NBTX

PRTC

RNLX

SXTP

TOVX

ZJYL

12 Health Care Stocks Moving In Monday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Karuna Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRTX#NASDAQ">KRTX</a>) shares increased by 47.4% to $317.1 during Monday's pre-market session. The company's market cap stands at $11.9 billion. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) shares rose 30.21% to $1.55. The company's market cap stands at $5.6 million. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) shares rose 26.97% to $0.56. The company's market cap stands at $24.8 million. </li>
<li>Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) shares increased by 17.9% to $0.87. The company's market cap stands at $78.6 million. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) shares increased by 14.14% to $0.51. The company's market cap stands at $19.6 million. </li>
<li>Atara Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) stock moved upwards by 13.45% to $0.51. The market value of their outstanding shares is at $51.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>AlloVir (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVR#NASDAQ">ALVR</a>) shares declined by 67.0% to $0.77 during Monday's pre-market session. The company's market cap stands at $87.8 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock declined by 37.5% to $2.25. The market value of their outstanding shares is at $1.8 million. </li>
<li>Castle Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSTL#NASDAQ">CSTL</a>) shares fell 26.58% to $16.0. The market value of their outstanding shares is at $430.5 million. </li>
<li>60 Degrees (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTP#NASDAQ">SXTP</a>) stock fell 19.55% to $0.89. The market value of their outstanding shares is at $5.1 million. </li>
<li>Nanobiotix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBTX#NASDAQ">NBTX</a>) shares fell 13.16% to $6.67. The market value of their outstanding shares is at $314.2 million. </li>
<li>Biofrontera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRI#NASDAQ">BFRI</a>) shares fell 12.39% to $2.83. The market value of their outstanding shares is at $4.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATRA

BFRI

CDTX

CSTL

SNTI

TRIB

12 Health Care Stocks Moving In Monday's Pre-Market Session

U.S. stocks traded mixed toward the end of trading, with the Dow Jones index turning lower on Friday.
The Dow traded down&nbsp;0.05% to 37,385.32 while the NASDAQ rose 0.12% to 14,982.36. The S&amp;P 500 also rose, gaining, 0.15% to 4,753.64.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/23/12/36360925/312m-bet-on-occidental-petroleum-check-out-these-4-stocks-insiders-are-buying"> $312M Bet On Occidental Petroleum? Check Out These 4 Stocks Insiders Are Buying</a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
&nbsp;
Consumer staples shares jumped by 0.9% on Friday.
In trading on Friday, consumer discretionary shares fell by 0.3%.
&nbsp;
<h3>Top Headline</h3>
&nbsp;
NIKE, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nke#NYSE">NKE</a>) posted better-than-expected earnings for its second quarter, but sales missed expectations.
Nike reported quarterly earnings of $1.03 per share, surpassing analyst expectations of 85 cents. Revenue of $13.39 billion missed the Street&#39;s estimate of $13.43 billion.
The company also stated that it is assessing opportunities to deliver up to $2 billion in cumulative cost savings during the next three years.
&nbsp;
<h3>Equities Trading UP</h3>
&nbsp;
Karuna Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/krtx#NASDAQ">KRTX</a>) shares shot up 47% to $316.66. Bristol Myers Squibb &amp; Co (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bmy#NYSE">BMY</a>) agreed to acquire Karuna Therapeutics for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired.
Shares of Royalty Management Holding Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rmco#NASDAQ">RMCO</a>) got a boost, surging 44% to $2.87 after the company said its unit Ferrox Holdings confirmed the commencement of production of titanium ferrite from its Tivani operating site.
Daseke, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dske#NASDAQ">DSKE</a>) shares were also up, gaining 65% to $8.11 after the company announced it will be acquired by TFI International.
&nbsp;
<h3>Equities Trading DOWN</h3>
&nbsp;
AlloVir, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alvr#NASDAQ">ALVR</a>) shares dropped 66% to $0.7808 after the company provided an update on its three Phase 3 clinical trials with posoleucel, an investigational off-the-shelf multi-virus-specific T cell therapy, which targets six viral pathogens in immunocompromised individuals: adenovirus (AdV), BK virus (BKV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), human herpesvirus-6 (HHV-6) and JC virus (JCV).
Shares of Advent Technologies Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adn#NASDAQ">ADN</a>) were down 35% to $0.2042 after the company announced a $2 million registered direct offering of common stock.
Netcapital Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ncpl#NASDAQ">NCPL</a>) was down, falling 36% to $0.2110 after the company announced pricing of a $4 million public offering.
Also Check This Out:<a href="https://www.benzinga.com/news/23/12/36361339/3-minutes-to-boost-your-earnings-3-high-yielding-dividend-stocks-in-defensive-sector-from-wall-stree"> 3 Minutes To Boost Your Earnings: 3 High-Yielding Dividend Stocks In Defensive Sector From Wall Street&#39;s Most Accurate Analysts</a>
&nbsp;
<h3>Commodities</h3>
&nbsp;
In commodity news, oil traded down 0.4% to $73.58 while gold traded up 0.6% at $2,064.00.
Silver traded down 0.1% to $24.575 on Friday while copper fell 0.3% to $3.9040.
&nbsp;
<h3>Euro zone</h3>
&nbsp;
European shares closed mostly higher today. The eurozone&rsquo;s STOXX 600 rose 0.14%, London&rsquo;s FTSE 100 rose 0.04% while Spain&rsquo;s IBEX 35 Index rose 0.08% The German DAX rose 0.11% French CAC 40 fell 0.03%, while Italy&rsquo;s FTSE MIB Index gained 0.26%.
The consumer confidence index in Italy climbed to 106.7 in December from 103.6 a month ago, while manufacturing confidence index fell to 95.4 in December from 96.6 in November. Spanish economy grew by 0.3% quarter-over-quarter during the third quarter.
Producer prices in the French domestic market rose by 2.4% month-over-month in November compared to a revised 0.1% decline a month ago, while consumer confidence increased to 89 in December versus a revised 88 in the prior month.
The British economy grew by 0.3% year-over-year in the third quarter, while current account deficit shrank to &pound;17.2 billion in the third quarter of versus a revised &pound;24.0 billion gap in the prior period. Retail sales in the U.K. rose by 1.3% from a month ago in November.
&nbsp;
<h3>Asia Pacific Markets</h3>
&nbsp;
Asian markets closed mixed on Friday, with Japan&rsquo;s Nikkei 225 gaining 0.09%, Hong Kong&rsquo;s Hang Seng Index falling 1.69% and China&rsquo;s Shanghai Composite Index falling 0.13%. India&rsquo;s S&amp;P BSE Sensex, meanwhile, rose 0.34%.
The annual inflation rate in Japan fell to 2.8% in November from 3.3% in the earlier month, while food prices in Japan increased by 7.3% from a year ago in November.
&nbsp;
<h3>Economics</h3>
&nbsp;
New orders for manufactured durable goods rose by 5.4% month-over-month in November.
Building permits in the U.S. declined by 2.1% to an annual rate of 1.467 million in November versus the preliminary estimate of 1.460 million.
Personal income in the U.S. rose by 0.4% month-over-month in November, while personal spending increased by 0.2% from a month ago in November.
Core PCE prices in the U.S. rose by 0.1% from the prior month in November. However, core prices rose by 3.2% from the prior year, compared to market estimates of 3.3%.
The University of Michigan&#39;s consumer sentiment was revised higher to 69.7 in December versus a preliminary reading of 69.4.
Sales of new single-family houses fell by 12.2% from the prior month to an annualized rate of 590 thousand in November.
The total number of active U.S. oil rigs fell by 3 this week, Baker Hughes Inc reported.
Now Read This: <a href="https://www.benzinga.com/news/23/12/36360929/top-4-tech-stocks-that-may-implode-this-month"> Top 4 Tech Stocks That May Implode This Month</a>

Shares of AAR Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/air#NYSE">AIR</a>) fell during Friday&rsquo;s session after the company reported mixed <a href="https://www.benzinga.com/news/earnings/23/12/36357897/aviation-service-provider-aar-posts-mixed-bag-of-q2-earnings-set-for-revenue-and-eps-boost-post-tri">second-quarter financial results.</a>
AAR reported quarterly sales of $545.4 million, up 16% Y/Y, missing the consensus of $557.2 million. Adjusted EPS from continuing operations rose 17% Y/Y to 81 cents, beating the consensus of 80 cents.
AAR recently disclosed the buyout of the Product Support business of Triumph Group Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tgi#NYSE">TGI</a>) for $725 million.
AAR shares fell 7% to $65.82 on Friday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>NextPlay Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nxtp#NASDAQ">NXTP</a>) shares jumped 263% to $3.29.</li>
<li>Jin Medical International Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zjyl#NASDAQ">ZJYL</a>) gained 71% to $120.50.</li>
<li>Daseke, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dske#NASDAQ">DSKE</a>) gained 64.8% to $8.10 after the company announced it will be acquired by TFI International.</li>
<li>Royalty Management Holding Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rmco#NASDAQ">RMCO</a>) jumped 59% to $3.18. Royalty Management Holding announced that Ferrox Holdings confirmed the commencement of production of titanium ferrite from its Tivani operating site.</li>
<li>Karuna Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/krtx#NASDAQ">KRTX</a>) shares gained 46.9% to $316.20. Bristol Myers Squibb &amp; Co (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bmy#NYSE">BMY</a>) agreed to acquire Karuna Therapeutics for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired.</li>
<li>Polished.com Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pol#NYSE">POL</a>) rose 46% to $5.91.</li>
<li>Esports Entertainment Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gmbl#NASDAQ">GMBL</a>) jumped 40.8% to $5.92.</li>
<li>Argo Blockchain plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arbk#NASDAQ">ARBK</a>) gained 35% to $3.4801.</li>
<li>PureTech Health plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prtc#NASDAQ">PRTC</a>) climbed 33.8% to $24.95 after the company announced that its Founded Entity, Karuna Therapeutics, entered into a definitive merger agreement to be acquired by Bristol Myers Squibb.</li>
<li>Snow Lake Resources Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/litm#NASDAQ">LITM</a>) rose 29.6% to $1.1389.</li>
<li>Asset Entities Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/asst#NASDAQ">ASST</a>) rose 25.9% to $0.8310 after jumping 45% on Thursday. Asset Entities, last month, announced a stock repurchase program.</li>
<li>Rocket Lab USA, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rklb#NASDAQ">RKLB</a>) shares gained 25% to $5.54 after the company announced a new $515 million contract with a U.S. government customer.</li>
<li>Enlivex Therapeutics Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/enlv#NASDAQ">ENLV</a>) rose 23.6% to $2.8150. Enlivex Therapeutics recently announced that it completed enrollment of all 120 patients in its Phase II trial of Allocetra in patients with sepsis.</li>
<li>Atara Biotherapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/atra#NASDAQ">ATRA</a>) shares rose 22.4% to $0.5466 after the company announced the closing of the expanded global partnership with Pierre Fabre Laboratories for tabelecleucel.</li>
<li>Neumora Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nmra#NASDAQ">NMRA</a>) surged 20.2% to $16.81.</li>
<li>Canaan Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/can#NASDAQ">CAN</a>) gained 20% to $3.10.</li>
<li>Wheels Up Experience Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/up#NYSE">UP</a>) rose 19.3% to $3.2801.</li>
<li>Bitdeer Technologies Group (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/btdr#NASDAQ">BTDR</a>) gained 16.6% to $9.85.</li>
<li>MoneyLion Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ml#NYSE">ML</a>) surged 14.6% to $64.42.</li>
<li>Tourmaline Bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/trml#NASDAQ">TRML</a>) rose 14.3% to $23.01.</li>
<li>ALX Oncology Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alxo#NASDAQ">ALXO</a>) jumped 13.6% to $14.81.</li>
<li>Allogene Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/allo#NASDAQ">ALLO</a>) gained 13.5% to $3.1333.</li>
<li>Mineralys Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mlys#NASDAQ">MLYS</a>) rose 13% to $8.44. Mineralys said first subject dosed in Launch-HTN, the second pivotal trial of lorundrostat for treatment of hypertension.</li>
<li>ZIM Integrated Shipping Services Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/zim#NYSE">ZIM</a>) surged 11.5% to $11.71.</li>
<li>Jin Medical International Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zjyl#NASDAQ">ZJYL</a>) gained 11.5% to $78.62.</li>
<li>ImmunityBio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ibrx#NASDAQ">IBRX</a>) shares rose 11.2% to $4.5350 after declining 10% on Thursday.</li>
<li>Apogee Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/apge#NASDAQ">APGE</a>) jumped 10.3% to $28.17.</li>
<li>ANSYS, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/anss#NASDAQ">ANSS</a>) gained 10.2% to $334.05.</li>
<li>Fulcrum Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fulc#NASDAQ">FULC</a>) rose 10.2% to $6.36.</li>
<li>Prime Medicine, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prme#NASDAQ">PRME</a>) gained 9% to $9.55.</li>
<li>Compass, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/comp#NYSE">COMP</a>) gained 8.7% to $3.50.</li>
<li>Altair Engineering Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/altr#NASDAQ">ALTR</a>) surged 8.3% to $80.95 after JP Morgan initiated coverage on the stock with an Overweight rating and $86 price target.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>AlloVir, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alvr#NASDAQ">ALVR</a>) shares dipped 66.1% to $0.7904 after the company provided an update on its three Phase 3 clinical trials with posoleucel, an investigational off-the-shelf multi-virus-specific T cell therapy, which targets six viral pathogens in immunocompromised individuals: adenovirus (AdV), BK virus (BKV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), human herpesvirus-6 (HHV-6) and JC virus (JCV).</li>
<li>Jayud Global Logistics Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jyd#NASDAQ">JYD</a>) fell 46% to $1.49.</li>
<li>Netcapital Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ncpl#NASDAQ">NCPL</a>) shares fell 36% to $0.2114 after the company announced pricing of a $4 million public offering.</li>
<li>Advent Technologies Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adn#NASDAQ">ADN</a>) shares fell 34.2% to $0.2050 after announcing a $2 million registered direct offering of common stock.</li>
<li>Banyan Acquisition Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/byn#NYSE">BYN</a>) fell 28.5% to $7.79.</li>
<li>ParaZero Technologies Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/przo#NASDAQ">PRZO</a>) dipped 27% to $1.1700.</li>
<li>Linkage Global Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lgcb#NASDAQ">LGCB</a>) fell 24.4% to $1.77. Linkage Global recently priced&nbsp;$6 million initial public offering of 1.5 million ordinary shares at $4 per share.</li>
<li>Cemtrex, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cetx#NASDAQ">CETX</a>) fell 20.3% to $5.18 following quarterly results.</li>
<li>ATIF Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/atif#NASDAQ">ATIF</a>) dipped 20% to $0.8390.</li>
<li>Lottery.com Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ltry#NASDAQ">LTRY</a>) fell 18% to $3.01.The company&rsquo;s shares jumped 196% on Thursday after the company announced an $18 million investment commitment from Prosperity Investment Management.</li>
<li>60 Degrees Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sxtp#NASDAQ">SXTP</a>) shares fell 17.3% to $0.9103 after declining around 6% on Thursday.</li>
<li>Cyclacel Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cycc#NASDAQ">CYCC</a>) fell 17.1% to $2.9850 after the company announced a registered direct and private placement offering priced at-the-market under Nasdaq rules.</li>
<li>Brooge Energy Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/brog#NASDAQ">BROG</a>) fell 16.4% to $3.3590.</li>
<li>Mullen Automotive, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/muln#NASDAQ">MULN</a>) shares fell 15.9% to $11.98. Mullen Automotive shares jumped 78% on Thursday amid increased volatility following the company&#39;s 1-for-100 reverse split, and after the company announced 38 additional Class 3 vehicles have been delivered to Randy Marion Automotive Group with the company invoicing RMA for $2.5 million.</li>
<li>NetEase, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ntes#NASDAQ">NTES</a>) fell 14.9% to $88.81 after China unveiled draft rules aimed at curbing spending on online gaming.</li>
<li>Nanobiotix S.A. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nbtx#NASDAQ">NBTX</a>) shares declined 13.8% to $6.62 after jumping more than 15% on Thursday.</li>
<li>NIKE, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nke#NYSE">NKE</a>) shares fell 10.8% to $109.31. NIKE posted better-than-expected earnings for its second quarter, but sales missed expectations. The company also stated that it is assessing opportunities to deliver up to $2 billion in cumulative cost savings during the next three years.</li>
<li>HUYA Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/huya#NYSE">HUYA</a>) shares declined 9.8% to $3.2750. HUYA entered into definitive agreement to acquire a global mobile application service provider.</li>
<li>Foot Locker, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fl#NYSE">FL</a>) declined 5.5% to $30.54. Shares of footwear and athletic apparel stocks traded lower in sympathy with Nike, which fell after reporting mixed second-quarter results, lowering its outlook and announcing cost savings plans.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/markets/cryptocurrency/23/12/36362345/ethereum-hits-2-300-following-pce-data-optimism-emerges-as-top-gainer"> Ethereum Hits $2,300 Following PCE Data; Optimism Emerges As Top Gainer</a>

ALLO

ALTR

ALXO

ANSS

APGE

ARBK

ASST

ATIF

BROG

BTDR

CETX

COMP

ENLV

FULC

GMBL

HUYA

IBRX

LGCB

LITM

LTRY

MLYS

MULN

NMRA

NTES

NXTP

PRME

PRZO

RKLB

TRML

Why AAR Shares Are Trading Lower By 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session

<h3>Gainers</h3>
<ul>
<li>Jin Medical International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZJYL#NASDAQ">ZJYL</a>) shares rose 85.2% to $130.55 during Friday's regular session. The company's market cap stands at $1.0 billion. </li>
<li>Karuna Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRTX#NASDAQ">KRTX</a>) stock increased by 47.07% to $316.5. The market value of their outstanding shares is at $11.9 billion. </li>
<li>IMAC Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BACK#NASDAQ">BACK</a>) shares rose 35.8% to $2.2. The market value of their outstanding shares is at $2.5 million. </li>
<li>PureTech Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTC#NASDAQ">PRTC</a>) shares increased by 28.15% to $24.4. The company's market cap stands at $663.5 million. </li>
<li>HeartBeam (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAT#NASDAQ">BEAT</a>) stock moved upwards by 24.84% to $2.07. The company's market cap stands at $54.5 million. </li>
<li>Neumora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRA#NASDAQ">NMRA</a>) shares increased by 23.73% to $17.31. The company's market cap stands at $2.6 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>AlloVir (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVR#NASDAQ">ALVR</a>) shares fell 65.7% to $0.8 during Friday's regular session. The company's market cap stands at $91.2 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares fell 22.09% to $2.81. The market value of their outstanding shares is at $2.3 million. </li>
<li>60 Degrees (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTP#NASDAQ">SXTP</a>) shares decreased by 20.46% to $0.88. The company's market cap stands at $5.0 million. </li>
<li>Nanobiotix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBTX#NASDAQ">NBTX</a>) shares decreased by 11.98% to $6.76. The market value of their outstanding shares is at $318.4 million. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) stock declined by 10.96% to $0.4. The company's market cap stands at $15.3 million. </li>
<li>GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) shares decreased by 10.54% to $0.33. The company's market cap stands at $1.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BEAT

12 Health Care Stocks Moving In Friday's Intraday Session

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 50 points on Friday.
The Dow traded up 0.16% to 37,465.58 while the NASDAQ rose 0.28% to 15,005.25. The S&amp;P 500 also rose, gaining, 0.28% to 4,759.82.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/23/12/36360925/312m-bet-on-occidental-petroleum-check-out-these-4-stocks-insiders-are-buying"> $312M Bet On Occidental Petroleum? Check Out These 4 Stocks Insiders Are Buying</a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
&nbsp;
Utilities shares jumped by 0.9% on Friday.
In trading on Friday, consumer discretionary shares fell by 0.4%.
&nbsp;
<h3>Top Headline</h3>
&nbsp;
The University of Michigan&#39;s consumer sentiment was revised higher to 69.7 in December versus a preliminary reading of 69.4.
&nbsp;
<h3>Equities Trading UP</h3>
&nbsp;
Karuna Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/krtx#NASDAQ">KRTX</a>) shares shot up 47% to $316.30. Bristol Myers Squibb &amp; Co (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bmy#NYSE">BMY</a>) agreed to acquire Karuna Therapeutics for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired.
Shares of Royalty Management Holding Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rmco#NASDAQ">RMCO</a>) got a boost, surging 49% to $2.9650 after the company said its unit Ferrox Holdings confirmed the commencement of production of titanium ferrite from its Tivani operating site.
Daseke, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dske#NASDAQ">DSKE</a>) shares were also up, gaining 65% to $8.11 after the company announced it will be acquired by TFI International.
&nbsp;
<h3>Equities Trading DOWN</h3>
&nbsp;
AlloVir, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alvr#NASDAQ">ALVR</a>) shares dropped 66% to $0.7988 after the company provided an update on its three Phase 3 clinical trials with posoleucel, an investigational off-the-shelf multi-virus-specific T cell therapy, which targets six viral pathogens in immunocompromised individuals: adenovirus (AdV), BK virus (BKV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), human herpesvirus-6 (HHV-6) and JC virus (JCV).
Shares of Advent Technologies Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adn#NASDAQ">ADN</a>) were down 35% to $0.2050 after the company announced a $2 million registered direct offering of common stock.
Netcapital Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ncpl#NASDAQ">NCPL</a>) was down, falling 34% to $0.2194 after the company announced pricing of a $4 million public offering.
Also Check This Out:<a href="https://www.benzinga.com/news/23/12/36361339/3-minutes-to-boost-your-earnings-3-high-yielding-dividend-stocks-in-defensive-sector-from-wall-stree"> 3 Minutes To Boost Your Earnings: 3 High-Yielding Dividend Stocks In Defensive Sector From Wall Street&#39;s Most Accurate Analysts</a>
&nbsp;
<h3>Commodities</h3>
&nbsp;
In commodity news, oil traded up 0.1% to $73.92 while gold traded up 0.7% at $2,065.20.
Silver traded down 0.1% to $24.55 on Friday while copper fell 0.3% to $ 3.9040.
&nbsp;
<h3>Euro zone</h3>
&nbsp;
European shares were mostly higher today. The eurozone&rsquo;s STOXX 600 rose 0.14%, London&rsquo;s FTSE 100 rose 0.04% while Spain&rsquo;s IBEX 35 Index rose 0.08% The German DAX rose 0.11% French CAC 40 fell 0.03%, while Italy&rsquo;s FTSE MIB Index gained 0.26%.
The consumer confidence index in Italy climbed to 106.7 in December from 103.6 a month ago, while manufacturing confidence index fell to 95.4 in December from 96.6 in November. Spanish economy grew by 0.3% quarter-over-quarter during the third quarter.
Producer prices in the French domestic market rose by 2.4% month-over-month in November compared to a revised 0.1% decline a month ago, while consumer confidence increased to 89 in December versus a revised 88 in the prior month.
The British economy grew by 0.3% year-over-year in the third quarter, while current account deficit shrank to &pound;17.2 billion in the third quarter of versus a revised &pound;24.0 billion gap in the prior period. Retail sales in the U.K. rose by 1.3% from a month ago in November.
&nbsp;
<h3>Asia Pacific Markets</h3>
&nbsp;
Asian markets closed mixed on Friday, with Japan&rsquo;s Nikkei 225 gaining 0.09%, Hong Kong&rsquo;s Hang Seng Index falling 1.69% and China&rsquo;s Shanghai Composite Index falling 0.13%. India&rsquo;s S&amp;P BSE Sensex, meanwhile, rose 0.34%.
The annual inflation rate in Japan fell to 2.8% in November from 3.3% in the earlier month, while food prices in Japan increased by 7.3% from a year ago in November.
&nbsp;
<h3>Economics</h3>
&nbsp;
New orders for manufactured durable goods rose by 5.4% month-over-month in November.
Building permits in the U.S. declined by 2.1% to an annual rate of 1.467 million in November versus the preliminary estimate of 1.460 million.
Personal income in the U.S. rose by 0.4% month-over-month in November, while personal spending increased by 0.2% from a month ago in November.
Core PCE prices in the U.S. rose by 0.1% from the prior month in November. However, core prices rose by 3.2% from the prior year, compared to market estimates of 3.3%.
The University of Michigan&#39;s consumer sentiment was revised higher to 69.7 in December versus a preliminary reading of 69.4.
Sales of new single-family houses fell by 12.2% from the prior month to an annualized rate of 590 thousand in November.
Now Read This: <a href="https://www.benzinga.com/news/23/12/36360929/top-4-tech-stocks-that-may-implode-this-month"> Top 4 Tech Stocks That May Implode This Month</a>

Gold Moves Higher; US Consumer Sentiment Improves In December

Leerink Partners analyst Mani Foroohar downgrades AlloVir (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVR#NASDAQ">ALVR</a>) from Outperform to Market Perform and announces $1 price target.

Leerink Partners Downgrades AlloVir to Market Perform, Announces $1 Price Target

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 50 points on Friday.
Following the market opening Friday, the Dow traded up 0.14% to 37,458.12 while the NASDAQ rose 0.30% to 15,008.08. The S&amp;P 500 also rose, gaining, 0.31% to 4,761.25.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/23/12/36360925/312m-bet-on-occidental-petroleum-check-out-these-4-stocks-insiders-are-buying"> $312M Bet On Occidental Petroleum? Check Out These 4 Stocks Insiders Are Buying</a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
&nbsp;
Energy shares jumped by 0.8% on Friday.
In trading on Friday, consumer discretionary shares fell by 0.2%.
&nbsp;
<h3>Top Headline</h3>
&nbsp;
Core PCE prices in the U.S. rose by 0.1% from the prior month in November. When energy and food are excluded from the overall PCE basket, core PCE inflation eased to 3.2% year-on-year, down from 3.5% a month earlier and below the expected 3.3%.
&nbsp;
<h3>Equities Trading UP</h3>
&nbsp;
Karuna Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/krtx#NASDAQ">KRTX</a>) shares shot up 47% to $317.10. Bristol Myers Squibb &amp; Co (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bmy#NYSE">BMY</a>) agreed to acquire Karuna Therapeutics for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired.
Shares of Royalty Management Holding Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rmco#NASDAQ">RMCO</a>) got a boost, surging 99% to $3.95. Royalty Management Holding announced that Ferrox Holdings confirmed the commencement of production of titanium ferrite from its Tivani operating site.
NextPlay Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nxtp#NASDAQ">NXTP</a>) shares were also up, gaining 102% to $1.8297.
&nbsp;
<h3>Equities Trading DOWN</h3>
&nbsp;
AlloVir, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alvr#NASDAQ">ALVR</a>) shares dropped 67% to $0.7699 after the company provided an update on its three Phase 3 clinical trials with posoleucel, an investigational off-the-shelf multi-virus-specific T cell therapy, which targets six viral pathogens in immunocompromised individuals: adenovirus (AdV), BK virus (BKV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), human herpesvirus-6 (HHV-6) and JC virus (JCV).
Shares of Cyclacel Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cycc#NASDAQ">CYCC</a>) were down 27% to $2.63 after the company announced a registered direct and private placement offering priced at-the-market under Nasdaq rules.
Netcapital Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ncpl#NASDAQ">NCPL</a>) was down, falling 40% to $0.1971 after the company announced pricing of a $4 million public offering.
Also Check This Out:<a href="https://www.benzinga.com/news/23/12/36361339/3-minutes-to-boost-your-earnings-3-high-yielding-dividend-stocks-in-defensive-sector-from-wall-stree"> 3 Minutes To Boost Your Earnings: 3 High-Yielding Dividend Stocks In Defensive Sector From Wall Street&#39;s Most Accurate Analysts</a>
&nbsp;
<h3>Commodities</h3>
&nbsp;
In commodity news, oil traded up 0.9% to $74.52 while gold traded up 1.4% at $2,080.20.
Silver traded up 0.8% to $24.77 on Friday while copper rose 0.3% to $3.9295.
&nbsp;
<h3>Euro zone</h3>
&nbsp;
European shares were mostly higher today. The eurozone&rsquo;s STOXX 600 rose 0.1%, London&rsquo;s FTSE 100 rose 0.1% while Spain&rsquo;s IBEX 35 Index rose 0.3% The German DAX rose 0.2% French CAC 40 rose 0.1%, while Italy&rsquo;s FTSE MIB Index gained 0.2%.
The consumer confidence index in Italy climbed to 106.7 in December from 103.6 a month ago, while manufacturing confidence index fell to 95.4 in December from 96.6 in November. Spanish economy grew by 0.3% quarter-over-quarter during the third quarter.
Producer prices in the French domestic market rose by 2.4% month-over-month in November compared to a revised 0.1% decline a month ago, while consumer confidence increased to 89 in December versus a revised 88 in the prior month.
The British economy grew by 0.3% year-over-year in the third quarter, while current account deficit shrank to &pound;17.2 billion in the third quarter of versus a revised &pound;24.0 billion gap in the prior period. Retail sales in the U.K. rose by 1.3% from a month ago in November.
&nbsp;
<h3>Asia Pacific Markets</h3>
&nbsp;
Asian markets closed mixed on Friday, with Japan&rsquo;s Nikkei 225 gaining 0.09%, Hong Kong&rsquo;s Hang Seng Index falling 1.69% and China&rsquo;s Shanghai Composite Index falling 0.13%. India&rsquo;s S&amp;P BSE Sensex, meanwhile, rose 0.34%.
The annual inflation rate in Japan fell to 2.8% in November from 3.3% in the earlier month, while food prices in Japan increased by 7.3% from a year ago in November.
&nbsp;
<h3>Economics</h3>
&nbsp;
New orders for manufactured durable goods rose by 5.4% month-over-month in November.
Building permits in the U.S. declined by 2.1% to an annual rate of 1.467 million in November versus the preliminary estimate of 1.460 million.
Personal income in the U.S. rose by 0.4% month-over-month in November, while personal spending increased by 0.2% from a month ago in November.
Core PCE prices in the U.S. rose by 0.1% from the prior month in November. However, core prices rose by 3.2% from the prior year, compared to market estimates of 3.3%.
Now Read This: <a href="https://www.benzinga.com/news/23/12/36360929/top-4-tech-stocks-that-may-implode-this-month"> Top 4 Tech Stocks That May Implode This Month</a>

Dow Rises 50 Points; Fed's Preferred Inflation Gauge Cools In November

Piper Sandler analyst Christopher Raymond downgrades AlloVir (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVR#NASDAQ">ALVR</a>) from Overweight to Neutral and lowers the price target from $27 to $1.5.

Piper Sandler Downgrades AlloVir to Neutral, Lowers Price Target to $1.5

JP Morgan analyst Anupam Rama downgrades AlloVir (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVR#NASDAQ">ALVR</a>) from Overweight to Underweight.

JP Morgan Downgrades AlloVir to Underweight

AlloVir Inc&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alvr#NASDAQ">ALVR</a>) provided an update on its three Phase 3 clinical trials with posoleucel, an investigational off-the-shelf multi-virus-specific T cell therapy, which targets six viral pathogens in immunocompromised individuals: adenovirus (AdV), BK virus (BKV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), human herpesvirus-6&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/23/12/g36359168/allovir-provides-updates-on-phase-3-clinical-development-program-for-posoleucel-an-allogeneic-viru" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">(HHV-6) and JC virus (JCV)</a>.&nbsp;
The company will discontinue its three global Phase 3 posoleucel studies &ndash; for prevention of clinically significant infections or diseases by multiple viruses, treatment of virus-associated hemorrhagic cystitis (vHC), and treatment of adenovirus (AdV) &ndash; following allogeneic hematopoietic cell transplant (allo-HCT).&nbsp;
The company determined following three pre-planned analyses by three independent Data Safety Monitoring Boards (DSMBs), each of which recommended stopping its respective trial for futility after a review of the data suggesting that each study was unlikely to meet its primary endpoint.&nbsp;
No safety concerns were observed or raised by any of the DSMBs.
AlloVir is in the process of notifying regulatory agencies and clinical trial investigators involved in these trials of the findings.
&quot;While we are disappointed by the unexpected outcome of these trials, we are encouraged by the apparent safety profile of posoleucel,&quot; said Diana Brainard, CEO.&nbsp;
&quot;In light of the DSMB recommendations, we will discontinue the prevention, vHC, and AdV Phase 3 trials. We will continue to analyze the data from these studies to understand any variables that may have impacted outcomes or any apparent subpopulation benefits.&quot;
AlloVir will review strategic alternatives for the company and its portfolio of virus-specific T-cell therapies. Such alternatives may include a merger, sale, divestiture of assets, licensing, or other strategic transaction.&nbsp;
As of September 30, 2023, AlloVir had cash, cash equivalents, and short-term investments of $213.3 million.
Price Action:&nbsp;ALVR shares are down 64.4% at $0.83 during the premarket session on the last check Friday.

Biotech

Health Care

General

Why Is Penny Stock Cell Therapy Focused AlloVir Stock Plummeting Today?

WIIM

AlloVir shares are trading lower after the company announced it will discontinue its three Phase 3 posoleucel studies following separate, pre-planned DSMB futility analyses concluding the studies were unlikely to meet their primary endpoints.

<h3>Gainers</h3>
<ul>
<li>Karuna Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRTX#NASDAQ">KRTX</a>) stock moved upwards by 47.9% to $318.17 during Friday's pre-market session. The company's market cap stands at $12.0 billion. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) stock moved upwards by 29.29% to $0.57. The market value of their outstanding shares is at $25.2 million. </li>
<li>SenesTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNES#NASDAQ">SNES</a>) stock increased by 23.89% to $0.94. </li>
<li>Galecto (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLTO#NASDAQ">GLTO</a>) shares increased by 19.81% to $0.74. The market value of their outstanding shares is at $20.1 million. </li>
<li>TC BioPharm (Holdings) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) stock increased by 15.99% to $2.9. The company's market cap stands at $1.9 million. </li>
<li>Reviva Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVPH#NASDAQ">RVPH</a>) shares moved upwards by 14.28% to $4.4. The company's market cap stands at $122.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>AlloVir (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVR#NASDAQ">ALVR</a>) shares declined by 57.5% to $0.99 during Friday's pre-market session. The market value of their outstanding shares is at $112.9 million. </li>
<li>60 Degrees (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTP#NASDAQ">SXTP</a>) stock decreased by 14.11% to $0.94. The market value of their outstanding shares is at $5.4 million. </li>
<li>Nanobiotix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBTX#NASDAQ">NBTX</a>) stock declined by 12.77% to $6.7. The company's market cap stands at $315.6 million. </li>
<li>DMK Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMK#NASDAQ">DMK</a>) shares decreased by 12.4% to $0.67. The market value of their outstanding shares is at $6.7 million. </li>
<li>Oncternal Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCT#NASDAQ">ONCT</a>) stock decreased by 11.52% to $0.57. The company's market cap stands at $33.3 million. </li>
<li>ThermoGenesis Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THMO#NASDAQ">THMO</a>) shares fell 10.76% to $0.52. The company's market cap stands at $1.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GLTO

ONCT

RVPH

SNES

TCBP

THMO

12 Health Care Stocks Moving In Friday's Pre-Market Session

As of September 30, 2023,&nbsp;AlloVir&nbsp;had cash, cash equivalents and short-term investments of&nbsp;$213.3 million.

AlloVir Says It Will Discontinue Its Three Phase 3 Posoleucel Studies Following Separate, Pre-planned DSMB Futility Analyses Concluding Studies Were Unlikely To Meet Primary Endpoints

<h3>Gainers</h3>
<ul>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) stock rose 30.2% to $0.27 during Tuesday's after-market session. Today's trading volume for this security ended up closing at 1.8 million shares, which is 104.8 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $1.3 million. </li>
<li>Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) shares rose 11.57% to $1.35. The market value of their outstanding shares is at $40.9 million. </li>
<li>GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) shares increased by 10.08% to $1.2. The company's market cap stands at $3.5 million. </li>
<li>Vicarious Surgical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBOT#NYSE">RBOT</a>) shares moved upwards by 10.06% to $0.41. The company's market cap stands at $70.6 million. </li>
<li>AcelRx Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRX#NASDAQ">ACRX</a>) shares increased by 9.8% to $0.56. The market value of their outstanding shares is at $9.1 million. </li>
<li>AlloVir (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVR#NASDAQ">ALVR</a>) shares increased by 9.15% to $1.55. The company's market cap stands at $176.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Tharimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THAR#NASDAQ">THAR</a>) shares declined by 20.6% to $0.2 during Tuesday's after-market session. This security traded at a volume of 559.5K shares come close, making up 35.3% of its average volume over the last 100 days. The market value of their outstanding shares is at $3.5 million. </li>
<li>Biocept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOC#NASDAQ">BIOC</a>) shares declined by 17.27% to $0.36. Today's trading volume for this security ended up closing at 129.0K shares, which is 6.1 percent of its average volume over the last 100 days. </li>
<li>Sonnet BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) shares fell 13.26% to $1.57. The market value of their outstanding shares is at $2.7 million. </li>
<li>Motus GI Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOTS#NASDAQ">MOTS</a>) shares fell 11.37% to $0.59. Motus GI Hldgs's trading volume hit 1.6 million shares by close, accounting for 1949.9% of its average volume over the last 100 days. The market value of their outstanding shares is at $3.4 million. </li>
<li>IO Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOBT#NASDAQ">IOBT</a>) stock decreased by 9.35% to $0.97. The company's market cap stands at $63.9 million. </li>
<li>Titan Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTNP#NASDAQ">TTNP</a>) shares fell 9.16% to $0.35. The company's market cap stands at $5.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACRX

BIOC

CGTX

IOBT

MOTS

RBOT

RSLS

SONN

THAR

TTNP

12 Health Care Stocks Moving In Tuesday's After-Market Session

U.S. stocks traded higher, with the Dow Jones falling around 180 points on Friday. Here are some big stocks recording losses in today&rsquo;s session.
<ul>
<li>PTC Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ptct#NASDAQ">PTCT</a>) dipped 31.6% to $25.56 after the company announced the CHMP has given a negative opinion on the conversion of the conditional marketing authorization to full marketing authorization of Translarna for the treatment of nmDMD.</li>
<li>GDEV Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gdev#NASDAQ">GDEV</a>) shares declined 16.4% to $3.09.</li>
<li>Planet Fitness, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/plnt#NYSE">PLNT</a>) shares tumbled 15.2% to $50.74 after the company announced Craig R. Benson has been appointed the interim CEO, succeeding Chris Rondeau.</li>
<li>Mitek Systems, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mitk#NASDAQ">MITK</a>) shares declined 10.7% to $11.58 after the company reported results for its second quarter and reiterated its FY23 guidance.</li>
<li>Kemper Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/kmpr#NYSE">KMPR</a>) shares fell 10.5% to $45.67. Kemper named Senior Vice President and Treasurer Bradley T. Camden as interim Chief Financial Officer, effective immediately and said it is initiating formal search process for a permanent Chief Financial Officer.</li>
<li>Kaixin Auto Holdings (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kxin#NASDAQ">KXIN</a>) shares dipped 9.6% to $2.94.</li>
<li>The Vita Coco Company, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/coco#NASDAQ">COCO</a>) shares fell 9.4% to $26.08.</li>
<li>Ambrx Biopharma Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amam#NASDAQ">AMAM</a>) fell 8.4% to $9.10.</li>
<li>Perfect Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/perf#NYSE">PERF</a>) fell 8.3% to $3.2150.</li>
<li>Iris Energy Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/iren#NASDAQ">IREN</a>) fell 8.2% to $4.60. The company posted net loss after income tax of $171.9 million for FY23, versus a $419.8 million loss in fiscal year 2022.</li>
<li>FingerMotion, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fngr#NASDAQ">FNGR</a>) dipped 8.2% to $6.44.</li>
<li>Super Micro Computer, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smci#NASDAQ">SMCI</a>) declined 7.7% to $249.93.</li>
<li>Lindsay Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lnn#NYSE">LNN</a>) fell 7.7% to $117.97. Stifel downgraded Lindsay from Buy to Hold and lowered the price target from $146 to $135.</li>
<li>ProKidney Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prok#NASDAQ">PROK</a>) fell 7.5% to $6.44.</li>
<li>AlloVir, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alvr#NASDAQ">ALVR</a>) fell 6.8% to $2.5250.</li>
<li>Hovnanian Enterprises, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hov#NYSE">HOV</a>) fell 6% to $109.96.</li>
<li>The Aaron&#39;s Company, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/aan#NYSE">AAN</a>) fell 5.7% to $9.83.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/23/09/34610362/top-5-consumer-stocks-that-may-collapse-this-quarter"> Top 5 Consumer Stocks That May Collapse This Quarter</a>

AMAM

COCO

FNGR

GDEV

IREN

KMPR

KXIN

MITK

PERF

PLNT

PROK

PTCT

SMCI

PTC Therapeutics, Planet Fitness, Kemper And Other Big Stocks Moving Lower On Friday

Leerink Partners analyst Mani Foroohar reiterated a Hold rating on AlloVir (ALVR – Research Report) yesterday and set a price target of $1.00. Mani...

Maintaining a Hold: AlloVir's Strategic Uncertainty and Financial Outlook

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
AlloVir (NASDAQ:<a href="https://investorplace.com/stock-quotes/alvr-stock-quote/">ALVR</a>) just reported results for the fourth quarter of 2023.<ul><li>AlloVir reported earnings per share of -53 cents. This was below the analyst estimate for EPS of -43 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/03/alvr-stock-earnings-allovir-for-q4-of-2023/">ALVR Stock Earnings: AlloVir Misses EPS for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ALVR Stock Earnings: AlloVir Misses EPS for Q4 2023

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
AlloVir (NASDAQ:<a href="https://investorplace.com/stock-quotes/alvr-stock-quote/">ALVR</a>) just reported results for the first quarter of 2024.<ul><li>AlloVir reported earnings per share of -26 cents. This was below the analyst estimate for EPS of -18 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/alvr-stock-earnings-allovir-for-q1-of-2024/">ALVR Stock Earnings: AlloVir Misses EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ALVR Stock Earnings: AlloVir Misses EPS for Q1 2024

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on AlloVir (ALVR – Research Report), Guardant Health ...

Analysts Have Conflicting Sentiments on These Healthcare Companies: AlloVir (ALVR), Guardant Health (GH) and Centessa Pharmaceuticals (CNTA)

AlloVir (ALVR) has issued an update. AlloVir, Inc.'s board, guided by its compensation committee, has sanctioned a potential $100,000 cash bonus fo...

AlloVir Approves Executive Bonuses for Potential 2024 Buyout

AlloVir (ALVR) has provided an announcement. AlloVir, Inc. has finalized a deal with AMAG Pharmaceuticals, Inc. to terminate a sublease agreement f...

AlloVir Ends Lease Agreement with AMAG Pharmaceuticals

AlloVir (ALVR) has issued an update. AlloVir, Inc. has finalized a deal to exit their lease for a property in Waltham, MA, by agreeing to a $7 mill...

AlloVir Finalizes $7 Million Lease Termination Deal

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
AlloVir (NASDAQ:<a href="https://investorplace.com/stock-quotes/alvr-stock-quote/">ALVR</a>) just reported results for the second quarter of 2024.<ul><li>AlloVir reported earnings per share of -5 cents. This was above the analyst estimate for EPS of -9 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/alvr-stock-earnings-allovir-for-q2-of-2024/">ALVR Stock Earnings: AlloVir Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ALVR Stock Earnings: AlloVir Beats EPS for Q2 2024

In a report released today, Michael Ulz from Morgan Stanley maintained a Sell rating on AlloVir (ALVR – Research Report), with a price target of $0...

Morgan Stanley Sticks to Its Sell Rating for AlloVir (ALVR)

In a report released on August 9, Mani Foroohar from Leerink Partners maintained a Hold rating on AlloVir (ALVR – Research Report), with a price ta...

Maintaining Hold on AlloVir Amid Financial Performance and Strategic Uncertainty

CNTA

Legal

Press Releases

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AlloVir, Inc. of Class Action Lawsuit and Upcoming Deadlines – ALVR

ALVR DEADLINE ALERT: ROSEN, A LEADING AND RANKED FIRM, Encourages AlloVir, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important March 19 Deadline in Securities Class Action – ALVR

ALLOVIR DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against AlloVir, Inc. and Encourages Investors to Contact the Firm

ALVR DEADLINE TUESDAY: ROSEN, A LEADING LAW FIRM, Encourages AlloVir, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ALVR

ALLOVIR, INC. (NASDAQ: ALVR) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against AlloVir, Inc.

FINAL ALVR DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds AlloVir Inc. Investors to Join the Class Action Lawsuit!

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allovir

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AlloVir, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALVR

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Comments

AlloVir

AlloVir (ALVR) Forecast

AlloVir (NASDAQ:ALVR) Stock, Quote.Headers.trade-ideas